Skip to main
SMMT
SMMT logo

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics (SMMT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 28%
Hold 17%
Sell 6%
Strong Sell 0%

Bulls say

Summit Therapeutics Inc. exhibits a promising outlook based on the favorable early data from its HARMONi trial, where approximately 65% of participating patients have demonstrated a progression-free survival benefit, suggesting strong efficacy potential for its product candidate, ridinilazole. Additionally, positive projections for the ongoing Phase 3 trials in non-small cell lung cancer (NSCLC) further bolster confidence, with an anticipated significant improvement in overall survival metrics and a possible translation of progression-free survival benefits into a 30%-50% enhancement in median overall survival. The company's strategic positioning within an evolving market, where successful outcomes could lead to substantial revenue potential, reflects a robust growth trajectory, drawing parallels to established players like KEYTRUDA.

Bears say

The financial outlook for Summit Therapeutics Inc is negatively impacted by a bear case scenario that suggests a marginal clinical efficacy or new safety signals emerging in the Phase 3 study, which could significantly lower the probability of success for its product candidate, Ivo, to just 20%. Additionally, the company faces substantial risks, including a lack of differentiated clinical data and potential competitive drug approvals, which may hinder the sales potential of its products. Furthermore, there are concerns regarding regulatory risks, delays in development, clinical trial failures, and potential medium-term dilution risks that collectively contribute to an estimated net loss of $0.32 per share.

Summit Therapeutics (SMMT) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 28% recommend Buy, 17% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Summit Therapeutics (SMMT) Forecast

Analysts have given Summit Therapeutics (SMMT) a Buy based on their latest research and market trends.

According to 18 analysts, Summit Therapeutics (SMMT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Summit Therapeutics (SMMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.